Overview

Long-Term Study of MP-214 in Patients With Schizophrenia

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Risperidone